ASLAN Pharmaceuticals Ltd — Form D
ASLAN Pharmaceuticals Ltd of SINGAPORE, U0, a company, filed a Form D exempt-offering notice with the SEC on 2023-04-26. The offering totals $100.0M, of which $20.0M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2023-04-26
- Form: D
- Accession: 0001722926-23-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $100.0M
- Amount sold: $20.0M
- Remaining: $80.0M
- Investors: 7
- Date of first sale: 2023-02-27
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-480087
Issuer
- Name: ASLAN Pharmaceuticals Ltd
- CIK: 0001722926
- Entity type: Other
- Jurisdiction: CAYMAN ISLANDS
- Address: 3 TEMASEK AVENUE, SINGAPORE, U0, 039190
- Phone: 65 6817 9598
Officers, directors & promoters (10)
| Name | Role | Location |
|---|
| Alexandre M Kaoukhov | Executive Officer | Singapore, U0 |
| Carl Firth, Ph.D. | Director | Singapore, U0 |
| Carl Firth, Ph.D. | Executive Officer | Singapore, U0 |
| Neil Graham, MBBS, M.D., MPH | Director | Singapore, U0 |
| Ben M Goodger | Executive Officer | Singapore, U0 |
| Stephen M Doyle | Executive Officer | Singapore, U0 |
| Andrew Howden | Director | Singapore, U0 |
| Kiran Asarpota | Executive Officer | Singapore, U0 |
| Robert E Hoffman | Director | Singapore, U0 |
| Kathleen M Metters | Director | Charlottesville, VA |
Other filings by this issuer (1)
More